Omeprazol Zentiva (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Zentiva, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid secretion and is employed to treat conditions such as gastro‑esophageal reflux disease, peptic ulcer disease, erosive esophagitis and as part of Helicobacter pylori eradication regimens.

GNH USA supplies Omeprazol Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Omeprazole is a proton pump inhibitor used to reduce gastric acid production in several acid‑related disorders.

- Gastro‑esophageal reflux disease: relief of heartburn and esophageal irritation. - Peptic ulcer disease: promotes ulcer healing and prevents recurrence. - Erosive esophagitis: heals erosive lesions and prevents further damage. - Helicobacter pylori eradication: used as part of combination therapy to increase eradication rates.

Omeprazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache - Abdominal pain - Nausea - Diarrhea

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis) - Clostridioides difficile infection - Low magnesium levels (hypomagnesemia) leading to cardiac arrhythmias

When prescribing omeprazole, clinicians should consider several precautionary measures to ensure safe use.

- Assess renal function: dose may need adjustment in severe renal impairment. - Monitor magnesium levels: prolonged therapy can cause hypomagnesemia. - Avoid abrupt discontinuation: may trigger rebound acid hypersecretion. - Use with caution in hepatic disease: drug is metabolized in the liver. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Omeprazole can affect the pharmacokinetics of several medicines, requiring attention to potential interactions.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect. - Atazanavir: decreased absorption and efficacy. - Methotrexate: increased toxicity risk. - Warfarin: possible increase in INR and bleeding risk.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum concentrations. - Diazepam: elevated levels may cause sedation. - Iron supplements: reduced iron absorption.